Prurigo Nodularis (PN) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Prurigo Nodularis (PN) is a skin disorder characterized by the formation of firm, itchy nodules on the skin’s surface. The intense itching (pruritus) associated with PN often prompts individuals to scratch excessively, leading to bleeding or discomfort and potentially exacerbating the condition by inducing additional skin lesions. The underlying pathophysiology of PN has been a subject of debate, with chronic or recurrent mechanical trauma or vigorous frictional pressure believed to induce epidermal hyperplasia, resulting in skin thickening. Diagnosing Prurigo nodularis primarily relies on clinical observation. Patients typically present with a history of persistent and severe itching, along with excoriations and flesh-colored or pink nodular lesions predominantly on extensor surfaces. Dermoscopy can be a valuable diagnostic aid, particularly in distinguishing PN from other dermatological conditions. Various topical treatments are available for managing Prurigo nodularis, including potent topical corticosteroids, intralesional corticosteroids, topical calcineurin inhibitors, topical capsaicin, and topical vitamin D analogs. Additionally, phototherapy options such as PUVA (psoralen combined with ultraviolet A) therapy, including bath or topical PUVA, long-wavelength ultraviolet A, narrowband ultraviolet B, and monochromatic excimer light of 308 nm, have demonstrated efficacy in improving PN nodules.
· According to epidemiological studies, Prurigo nodularis is relatively rare, with a prevalence estimated at 72 per 100,000 among US adults aged 18 to 64 with healthcare insurance.
Thelansis’s “Prurigo Nodularis (PN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prurigo Nodularis (PN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Prurigo Nodularis (PN) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Prurigo Nodularis (PN) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Tags: Prurigo Nodularis (PN), Prurigo Nodularis (PN) market outlook, Prurigo Nodularis (PN) competitive landscape, Prurigo Nodularis (PN) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)
